Article

OncLive® Forms New Strategic Alliance Partnership with UPMC CancerCenter

Author(s):

OncLive® and UPMC CancerCenter, partner with University of Pittsburgh Cancer Institute, have teamed up under OncLive's Strategic Alliance Partnership program.

OncLive® and UPMC CancerCenter, partner with University of Pittsburgh Cancer Institute, have teamed up under OncLive’s Strategic Alliance Partnership program. With the new agreement, OncLive will share news about the research and other programs conducted by UPMC CancerCenter in its fight against the disease.

OncLive will highlight the important work being done in UPMC CancerCenter’s research and clinical trials, as well as the innovative ways in which it uses smart technologies to treat patients. From cancer vaccine research happening in the laboratory to new precision therapies currently in clinical trials, UPMC CancerCenter’s work is far-reaching and cutting-edge. And through the development of Clinical Pathways, a web-based technology created by UPMC CancerCenter to provide physicians with evidence-based treatment protocols for cancer, they are helping to ensure consistent, high-quality care across the CancerCenter’s network of more than 40 locations.

Their expertise extends beyond the U.S. to several global partners in Ireland, Italy, Kazakhstan, Lithuania and Colombia, where they have established partnerships to enhance the delivery of cancer diagnosis and treatment in those countries.

“UPMC CancerCenter is dedicated to providing excellent patient care and essential clinical trials. But it also breaks new ground in other areas, like international healthcare and cutting-edge research,” said Mike Hennessy Jr., president of Intellisphere Oncology and Healthcare Specialty Group, part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH) family of businesses, which includes OncLive. “By partnering with UPMC CancerCenter, we can keep the community informed about its many important programs.”

UPMC CancerCenter recently became the first center in the region to use a new feature of the CyberKnife called the multileaf collimator that enables more highly targeted radiation treatment. The CancerCenter also utilizes a wide variety of smart technologies, including telemedicine, to expand the reach of oncology experts to remote locations.

“Our mission is to provide the best patient care possible, using all the tools at our disposal,” said Dr. Nancy E. Davidson, UPMC CancerCenter director.

“Together with OncLive, we are looking forward to sharing the stories of how our center breaks new ground in research, patient care and other surprising ways.” Hennessy added, “The Strategic Alliance Partnership program serves everyone committed to fighting cancer. When we work together and share our knowledge broadly, we are better armed to improve our efforts to overcome this devastating disease.”

About OncLive

OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News and Contemporary Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, based in Plainsboro, NJ. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURE® magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers and advocacy groups. To learn more, please visit http://www.OncLive.com.

About the UPMC CancerCenter

UPMC CancerCenter, with its partner, University of Pittsburgh Cancer Institute, treats 74,000 patients a year. UPMC CancerCenter focuses on 15 areas of cancer expertise, including sarcoma, head and neck cancers and liver cancer. Services range from prevention and detection to diagnosis and treatment. The center has 40 locations in Ohio, Pennsylvania, and West Virginia. One of its hospitals recently received its second consecutive Magnet award for excellence in nursing. For more information, please visit http://www.upmccancercenter.com.

Media Contacts

For UPMC CancerCenter: Jennifer Yates, 412-647-9966, yatesjc(at)upmc.edu For OncLive: Becky Taylor, 609-240-6886, becky(at)btaylorpa.com

Related Videos
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Adam M. Brufsky, MD, PhD, FACP
Video 8 - 2 KOLs are featured in, "Emerging Trials in the Management of HR+/HER2- mBC"
Video 7 - 2 KOLs are featured in, "Adverse Event Data and Management for Optimal Quality of Life in HR+/HER2- mBC"
Video 6 - 2 KOLs are featured in, "Other trials of note investigating targeted therapies in later line HR+/HER2- mBC"
Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, experts on breast cancer
Kathleen A. Dorritie, MD
Video 4 - 2 KOLs are featured in, "Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC"
Video 2 - 2 KOLs are featured in, "Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway"
This series features 2 KOLs